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Abstract
Background: phospholipid transfer protein (PLTP) plays important roles in lipoprotein metabolism and atherosclerosis 
and is expressed by macrophages and macrophage foam cells (MFCs). The aim of the present study was to determine 
whether the major protein from HDL, apoA-I, affects PLTP derived from MFCs.
Results: as cell model we used human THP-1 monocytes incubated with acetylated LDL, to generate MFC. The 
addition of apoA-I to the cell media increased apoE secretion from the cells, in a concentration dependent fashion, 
without affecting cellular apoE levels. In contrast, apoA-I had no effect on PLTP synthesis and secretion, but strongly 
induced the PLTP activity in the media. ApoA-I also increased phospholipid transfer activity of PLTP isolated from 
human plasma. This effect was dependent on apoA-I concentration but independent on apoA-I lipidation status. ApoE, 
ApoA-II and apoA-IV, but not immunoglobulins or bovine serum albumin, also increased PLTP activity. We also report 
that apoA-I protects PLTP from heat inactivation.
Conclusion: apoA-I enhances the phospholipid transfer activity of PLTP secreted from macrophage foam cells without 
affecting the PLTP mass.
Background
Atherosclerosis is an inflammatory disorder in the artery
wall caused by the accumulation of atherogenic lipopro-
teins such as low density lipoproteins (LDL) and triglyc-
eride rich remnant lipoproteins. In the artery wall these
lipoproteins are modified and taken up by macrophages.
This sterol loading of the macrophages promotes the for-
mation of macrophage foam cells (MFCs) essential con-
stituents of human atherosclerotic lesions [1]. Currently,
major efforts are made to develop therapies that will pro-
mote removal of cholesterol from lesion foam cells and
lead to regression of the atherosclerotic process [2]. Ani-
mal studies have shown that high density lipoproteins
(HDL) can promote the removal of cholesterol from the
arterial wall and transport it to the liver for excretion in a
process called reverse cholesterol transport (RCT) [3]. In
addition to RCT, HDL also has several other protective
functions such as antioxidant, antiinflammatory, vasodi-
lating and antithrombotic properties that contribute to
the strong independent inverse relationship with athero-
sclerotic cardiovascular disease [3].
Phospholipid transfer protein (PLTP) is expressed by
macrophages and the expression levels are increased in
MFCs due to LXR activation [4-6]. Bone marrow trans-
plantation studies in mice using PLTP deficient mac-
rophages gave conflicting results, and this treatment
either decreased [7] or increased atherosclerosis [8].
Mechanisms by which macrophage PLTP may be protec-
tive in atherogenesis involves the stabilization of ATP-
binding cassette transporter A1 (ABCA1) and stimula-
tion of cholesterol efflux [9,10], however, a recent study
suggests that elevation of PLTP in macrophage does not
affect RCT [11]. Furthermore, PLTP expression by mac-
rophages results in atherogenic effects on plasma lipids
and increased atherosclerotic lesion size [12].
Interestingly, it was shown that HDL levels are an
important determinant of PLTP levels and it was further
suggested that HDL might play a role in the stabilization
of PLTP [13,14]. To date, no detailed studies addressing
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the effect of apoA-I on PLTP expression and secretion
from human macrophages have been reported.
In the present study we have investigated the effect of
exogenous human apoA-I on the synthesis and secretion
of PLTP from human macrophage foam cells.
Methods
Cell culture, lipid loading and pharmacological treatments
Human THP-1 monocytes were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA). The monocytes were grown and maintained in
RPMI 1640 medium containing 10% (v/v) FBS, 10 mM
Hepes, pH 7.4, 100 U/mL penicillin, and 100 μg/mL
streptomycin at 37°C under 5% CO2 in a humidified incu-
bator. To differentiate the monocytes into macrophages,
the cells were plated onto 24-well plates and treated with
100 nM phorbol 12-myristate 13-acetate (PMA) (Sigma-
Aldrich, St. Louis, MO) in the growth medium for 72 h
prior to the experiment. The macrophages were loaded
by incubating them in the presence of 25 μg of protein/
well of acetylated LDL (AcLDL) in RPMI 1640 supple-
mented with 5% (v/v) fetal bovine lipoprotein deficient
serum (LPDS), 10 mM Hepes, pH 7.4, and penicillin/
streptomycin for 48 h. ApoE protein and PLTP mRNA,
protein and activity levels were assessed 24 h after incu-
bation in the presence or absence of apoA-I. The viability
and attachment of the cells were carefully evaluated by
light microscopy and protein measurements and no cyto-
toxic effects could be observed.
SDS-PAGE and Immunoblot Analysis
Equivalent amounts of protein from the cell lysate and
medium were subjected to Western blot analysis.
Medium was concentrated 50-fold for the detection of
apoE and PLTP. To detect apoE we used a monoclonal
antibody raised against the human apoE or a horseradish
peroxidase (HRP)-conjugated polyclonal antibody spe-
cific for human apoE (DAKO, Denmark). For PLTP detec-
tion we used a mouse monoclonal antibody (Mab59) or a
rabbit polyclonal antibody raised against purified human
plasma PLTP. Cellular actin was detected using a specific
rabbit polyclonal antibody (Santa Cruz).
ApoE ELISA
Human apoE was detected by ELISA as described previ-
o us ly [15]  wit h som e  m odifica t ions.  Brie fl y ,  w e  used a
polyclonal rabbit antibody (R107) as a capture antibody
to coat 96-well plates. As a detection antibody we used a
HRP-conjugated polyclonal antibody specific for human
apoE (DAKO, Denmark). Standard curve was prepared
using a standardized serum (Daichi, Japan).
Gene expression analyses
P L T P  m R N A  l e v e l s  w e r e  m e a s u r e d  b y  r e a l  t i m e  P C R
using as forward primer 5'-ACGCAGGGACGGTCCT-
GCTC-3' and as reverse primer 5'-CTCATTGAGCATG-
GGCATCACCCC-3' [5]. Cultured cells were
homogenized in RLT buffer (Qiagen, Valencia, CA) and
total RNA was isolated with RNeasy Mini kit (Qiagen)
according to the manufacturer's instructions. The total
RNA (2 μg) was reverse-transcribed by using Superscript
II (Invitrogen, Carlsbad, CA) and random hexamer prim-
ers (Applied Biosystems, Foster City, CA). Samples were
amplified in triplicate for PLTP and two housekeeping
genes, GAPDH and 18S rRNA, on a 7000 Sequence
Detection System (Applied Biosystems), using a SYBR-
green kit (Applied Biosystems).
Purification of PLTP from human plasma
PLTP was purified from human plasma according to
Marques-Vidal et al. [16]. Briefly, the human plasma frac-
tions, eluted from Butyl-Toyopearl 650(M) column, con-
taining PLTP activity were combined and applied to a
first heparin-sepharose column. After extensive washing
with the equilibration buffer, PLTP activity was eluted
with 25 mM Tris-HCl buffer, pH 7.40, containing 1 mM
EDTA and 1.0 M NaCl. The fractions containing PLTP
activity were combined, dialysed against 25 mM Tris-HCl
buffer, pH = 7.40, containing 1 mM EDTA, and applied to
a Mono Q HR 5/5 column, attached to a Merck HPLC
system. The column was eluted with a linear NaCl gradi-
ent (0-0.5 M) prepared in equilibration buffer. The frac-
tions containing PLTP activity were combined, dialysed
against 25 mM Tris-HCl buffer, pH 7.40, containing 1
mM EDTA and then applied on a second heparin-sephar-
ose column (Hi-Trap, 1 ml total volume, Pharmacia,
Upsala, Sweden). The column was then eluted with a lin-
ear NaCl gradient (0-0.5 M). Active fractions from the
Hi-Trap column were pooled and applied to a hydroxy-
lapatite column (2 ml total volume) previously equili-
brated with 1 mM Na-phosphate buffer, pH 6.80,
containing 150 mM NaCl. PLTP was eluted with a linear
Na-phosphate gradient (1-500 mM). PLTP activity eluted
at a phosphate concentration of 125-150 mM. PTLP
activity ranged between 2000 and 6000 nmol phospho-
lipid transferred/h/ml depending on the preparation and
was devoid of H-TGL, LCAT, phospholipase and CETP
activity.
PLTP activity
PLTP activity was measured using a radiometric method
as previously described [17]. Cholesterol loaded mac-
rophage media was 5-fold concentrated by ultrafiltration
and washed twice with PLTP activity assay buffer before
the activity was measured.
ApoA-I lipidation
For apoA-I lipidation we used increasing amounts of L-α-
Phosphatidylcholine (Sigma-Aldrich, St. Louis, MO). The
molar ratio of the proteoliposomes, apoA-I:PC:CHOL,Robciuc et al. Lipids in Health and Disease 2010, 9:59
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was as follow: 1:50:0, 1:50:7, 1:100:0, 1:100:7, 1:150:0 and
1:150:7. PC and CHOL were dried under nitrogen at
room temperature in glass tubes and resuspended in the
assay buffer (10 mM Tris-HCl, 1 mM EDTA, 140 mM
NaCl, pH 7.4). ApoA-I was added to the mixture at a con-
centration of 1 mg/ml. After the addition of Na-cholate
the samples were mixed gently avoiding foaming followed
by 20 minutes incubation at 24°C in a water bath with
gentle shaking. Finally the samples were dialyzed against
assay buffer for 20-40 hours and stored at + 4°C.
Results
Loading of THP-1 macrophages with AcLDL resulted in
an increase in apoE, PLTP and cholesteryl-ester transfer
protein (CETP) secretion (data not shown). When ApoA-
I was added to the media of cholesterol loaded mac-
rophages (Figure 1) the apoE secretion was increased.
ApoA-I addition did not affect the cellular content of
apoE (Figure 1, panel A and B). ApoE secretion from the
cells was measured by a specific ELISA in serum free
media containing 10, 20, 40 and 80 μg/ml apoA-I and a
concentration dependent induction in the secretion (up
to 5-fold) could be observed (Figure 1, panel C).
The stimulating effect of apoA-I on apoE secretion
from macrophages has been reported by several groups
and also confirmed by us in the present study. We further
investigated whether apoA-I also affects PLTP secretion
from macrophages, as both, PLTP and apoE, are known
to be important players in macrophage cholesterol
homeostasis and are associated with HDL or apoA-I [18].
Moreover, PLTP deletion from macrophages reduces
apoE secretion [19] suggesting that PLTP could play a
role in the apoA-I induced apoE secretion. Real time PCR
quantification showed no effect of apoA-I on PLTP
mRNA levels whereas all-trans retinoic acid (ATRA),
agonist for Retinoic X Receptor (RXR), induced a 3.5-fold
increase in the relative PLTP mRNA expression (Figure 2,
panel A). Western blot analysis revealed that, there was
no apoA-I mediated effect on cellular levels of PLTP and,
in contrast to apoE, also in the media PLTP levels
remained similar after the apoA-I addition (Figure 2,
panel B). In contrast, addition of an LXR agonist (22-OH
cholesterol) markedly increased PLTP secretion from the
cells (data not shown). PLTP activity in the media was 3-
fold increased by the addition of 10 μg/ml apoA-I,
Figure 1 Induction of apoE secretion by apoA-I in macrophage 
foam cells (MFCs). Panel A, apoE was analyzed by Western blot in the 
media and cellular lysate from lipid loaded macrophages incubated in 
the presence of 10 μg/ml apoA-I (apoA-I) or without (Control) for 24h. 
Panel B, bands were quantified (ImageJ v1.42q software) and the bars 
represent the intensity of apoE bands normalized to intensity of actin 
band. Panel C, increasing concentrations of apoA-I were added in the 
culture media of MFC and apoE concentration was quantified after 3h 
of incubation. ApoE concentration was determined by ELISA and val-
ues were normalized to total cell protein concentration. A linear rela-
tionship between apoA-I and apoE concentration was observed (R2 = 
0.959). The dots and error bars represent the mean ± SD calculated 
from triplicates. The results are representative for at least 3 indepen-
dent experiments.
Figure 2 Effect of apoA-I on PLTP derived from macrophage foam 
cells. Panel A, PLTP gene expression was analyzed by real-time PCR in 
untreated cells (Control) and cells treated with 10 μg/ml apoA-I for 24 
h (apoA-I). As a positive control induction of PLTP gene expression was 
measured after all-trans retinoic acid (ATRA) addition. To normalize the 
data we used as control two housekeeping genes, GAPDH and 18s rR-
NA. Panel B, PLTP was detected by Western blot in media and cell 
lysates from cells incubated in the presence (10 μg/ml) or in the ab-
sence (Control) of apoA-I. Actin was used as a reference. Panel C, PLTP 
activity measured in media from cells incubated in the presence (10 
μg/ml) or in the absence (Control) of apoA-I in the media. Bands repre-
sent the mean ± SD calculated from triplicates. Figures are representa-
tive for at least two independent experiments. ** P < 0.01.Robciuc et al. Lipids in Health and Disease 2010, 9:59
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although apoA-I had no effect on PLTP protein levels in
cell culture media (Figure 2, panel C).
Because the macrophage media also contains apoE that
presumably could mediate the apoA-I induction of PLTP
activity we also performed experiments where only puri-
fied human plasma PLTP and lipid free apoA-I were co-
incubated. ApoA-I significantly induced purified PLTP
activity in a concentration dependent manner (Figure 3,
panel A). To exclude the possibility that the effect
observed on PLTP activity could be due to the addition of
lipid free apoA-I in the PLTP assay reaction mixture, we
evaluated the phospholipid transfer of apoA-I in the
absence of PLTP. No phospholipid transfer could be
detected with 50 μg apoA-I, 4-fold higher than the high-
est amount of apoA-I used with PLTP (Figure 3, panel A).
The apoA-I mediated induction of purified PLTP activity
was abolished by a specific anti-apoA-I polyclonal anti-
body whereas the non-specific antibody had no effect on
the activity (Figure 3, panel B).
We have further questioned whether the observed
effect of apoA-I on PLTP activity depends on the apoA-I
lipidation or whether it is restricted to apoA-I only. T o
answer the first question, we have lipidated apoA-I with
increasing amounts of PC, as described in material and
methods. As depicted in figure 4 (panel A), increased
apoA-I lipidation did not have a significant effect on the
observed induction of PLTP activity. In addition, HDL
isolated from human plasma was equally effective in
inducing the PLTP activity. Furthermore, we also showed
that lipid-free apoA-II, apoA-IV and apoE induced puri-
fied PLTP activity to a similar extent as apoA-I (Figure 4,
panel B). In contrast, proteins not belonging to the apoli-
poprotein family of proteins such as rabbit non-specific
immunoglobulins and bovine serum albumin had no sig-
nificant effect on PLTP activity (Figure 4, panel B).
Plasma purified PLTP can be inactivated by heating at
56°C for one hour (Figure 5) [20]. To test if apoA-I can
protect PLTP from heat inactivation, we preincubated
purified PLTP from plasma with 20 μg apoA-I. Preincu-
bation of PLTP with apoA-I preserved the phospholipid
transfer activity, but the addition of apoA-I after heat
Figure 3 Effect of apoA-I on the activity human purified PLTP. 
Panel A, PLTP isolated from human plasma was pre-incubated for 2 
hours at room temperature in the presence of increasing concentra-
tions of apoA-I and thereafter assayed for phospholipid transfer activi-
ty. As a control, 50 μg apoA-I were added to the reaction mixture in the 
absence of PLTP. A linear relationship between apoA-I concentration 
and PLTP activity was observed (R2 = 0.969). Dots and error bars repre-
sent mean ± SD calculated from triplicates. Panel B, apoA-I was pre-in-
cubated with non-specific rabbit polyclonal antibodies (NS IgG) and 
anti-apoA-I rabbit polyclonal antibodies (R314) and the effects on PLTP 
activity were evaluated. Figures are representative for three indepen-
dent experiments. Bars and error bars represent mean ± SD calculated 
from triplicates. **P < 0.01.
Figure 4 The capacity of lipidated apoA-I and other apolipopro-
teins to induce PLTP activity. Panel A, PLTP was incubated for 2 
hours at room temperature in the presence of 10 μg/ml of lipid free 
apoA-I or lipidated with increasing amounts of phosphatidylcholine 
(PC) and cholesterol (CHOL) and 10 μg/ml HDL (representing a highly 
lipidated form of apoA-I) and assayed for the phospholipid transfer ac-
tivity. Panel B, PLTP was incubated for 2 hours at room temperature in 
the presence of 10 μg/ml of purified rabbit imunoglobulins (IgG), bo-
vine serum albumin (BSA), apoA-I, apoA-II, apoA-IV, apoE and HDL and 
analyzed for phospholipid transfer activity. Figures are representative 
for three independent experiments. Bars and error bars represent 
mean ± SD calculated from triplicates. * P < 0.05, **P < 0.01Robciuc et al. Lipids in Health and Disease 2010, 9:59
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inactivation of PLTP failed to recover the lost phospho-
lipid transfer activity (Figure 5). This shows that apoA-I
not only enhanced phospholipid transfer protein activity
of PLTP but has also a stabilizing effect.
Finally, because apoA-I enhances both PLTP activity
and apoE secretion from MFC we questioned whether
apoA-I mediate its effect on apoE secretion by enhancing
the PLTP activity. To test this we added plasma purified
PLTP in the media of MFC and evaluated the apoE secre-
t i o n  us i n g  ELIS A.  As  d e p i ct ed  i n  fi gu r e  6 ,  a d d i t i o n  o f
PLTP (200 nmol/ml/h) was equally ineffective in stimu-
lating apoE secretion from MFC as the addition of bovine
serum albumin.
Discussions
PLTP synthesized by macrophage and MFCs has been
associated with the development of atherosclerosis. In
the current study we investigated the effect of apoA-I on
PLTP secreted from MFC.
Our results confirm existing data which show that
apoA-I strongly stimulates apoE secretion from mac-
rophages, an effect that is likely to contribute to the anti-
atherogenic potential of HDL. Interestingly, the
enhancement of apoE secretion induced by apoA-I is
concentration dependent, but even at levels as high as 80
μg/ml a saturation of the system could not be demon-
strated. This suggests that the system capacity is very
high and can have important consequences in MFCs
physiology as well as in plasma lipoprotein metabolism.
PLTP secreted by macrophages contributes signifi-
cantly to total plasma phospholipid transfer activity [7].
The plasma PLTP pool derived from macrophages has
most probably a major impact on plasma lipoprotein
metabolism and atherogenesis. In the present study we
demonstrate that apoA-I does not affect PLTP secretion
from macrophages but instead increases PLTP facilitated
phospholipid transfer activity. The induction of phospho-
lipid transfer is due to a direct effect of apoA-I on PLTP
since the incubation of purified PLTP in the presence of
apoA-I resulted in an effect similar to that observed with
macrophage derived PLTP. These in vitro observations
suggest that this effect most probably is valid for PLTP
secreted from other tissues. Indeed, the PLTP activity in
ABCA1 deficiency, that results in very low levels of apoA-
I and HDL in plasma, is significantly reduced [13,14]. The
effect we report here is specific not only for apoA-I since
an increase of PLTP activity was also observed following
incubation in the presence of other apolipoproteins such
as apoA-II, apoA-IV and apoE. This suggests that PLTP
requires interactions with proteins containing amphip-
athic α-helix domains for proper lipid transfer activity.
Interestingly, similar structural characteristics are needed
for the induction of apoE secretion from macrophages
[21].
It is well known that PLTP is associated in plasma with
HDL [22] and the particles containing PLTP are highly
variable regarding the phospholipid transfer capacity
[23]. It is not clear yet what is the determining factor for
the differences in the PLTP activity and this remains to be
established [24,25]. Although the interaction of PLTP
with lipoprotein surfaces is an obligatory component of
lipid transfer, so far, it was not clearly demonstrated that
apoA-I and HDL can actually enhance PLTP activity.
It was recently reported that macrophage PLTP defi-
ciency causes a significant reduction of apoE secretion in
vivo [19]. The mechanism behind this observation is not
known but it may involve the stabilizing effect of PLTP on
ABCA1, known to be responsible for basal apoE secre-
tion [21]. A second possibility is that PLTP could mediate
HDL induced secretion of apoE from macrophages. Our
observations, that apoA-I does not affect the synthesis
and secretion of PLTP from macrophages and that
Figure 5 Stabilizing effect of apoA-I on PLTP activity. PLTP was in-
cubated at 58°C for 1 hour in the presence or absence of 20 μg apoA-I 
and assayed for the phospholipid transfer activity. Figure is representa-
tive for two independent experiments performed with two different 
PLTP batches. Bars represent mean ± SD calculated from duplicates. 
*20 μg apoA-I was added to PLTP after the incubation at 58°C for 1 
hour.
Figure 6 Effect of PLTP on apoE secretion. ApoE was analyzed by 
ELISA in the media from MFC incubated with 10 μg/ml bovine serum 
albumin (BSA), 10 μg/ml apoA-I (apoA-I) or with 200 nmol/ml/h PLTP 
for 24h. Figure is representative for two independent experiments. Bars 
represent mean ± SD calculated from triplicates. * P < 0.05.Robciuc et al. Lipids in Health and Disease 2010, 9:59
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increased PLTP activity in macrophage media, by addi-
tion of exogenous active PLTP, do not increase apoE
secretion from macrophages, are indirect evidence that
the first hypothesis is more likely.
Conclusions
In summary, we have demonstrated that, in cholesterol
loaded macrophages, apoA-I does not affect PLTP syn-
thesis or secretion but increases PLTP mediated phos-
pholipid transfer activity. The same was observed with
purified plasma PLTP and the effect was independent on
apoA-I lipidation status and could be demonstrated by
other proteins containing amphipathic α-helix domains.
We also provide evidence that the apoA-I induced apoE
secretion from macrophages and the enhancement of
PLTP activity by apoA-I are unrelated phenomena.
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